An open-label, exploratory clinical trial to investigate the effects of Ginkgo biloba special extract EGb 761 on dopamine-induced executive cognitive functions and their neurophysiological correlation in subjects with mild cognitive deficits.

Trial Profile

An open-label, exploratory clinical trial to investigate the effects of Ginkgo biloba special extract EGb 761 on dopamine-induced executive cognitive functions and their neurophysiological correlation in subjects with mild cognitive deficits.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2011

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Mild cognitive impairment
  • Focus Pharmacodynamics
  • Sponsors Dr. Willmar Schwabe Group
  • Most Recent Events

    • 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 14 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top